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Marijuana has become the most commonly detected non-alcohol substance among drivers in the United States
and Europe. Use of marijuana has been shown to impair driving performance and increase crash risk. Due to the
lack of standardization in assessing marijuana-induced impairment and limitations of zero tolerance legislation, more
jurisdictions are adopting per se laws by specifying a legal limit of Δ9-tetrahydrocannabinol (THC) at or above which
drivers are prosecuted for driving under the influence of marijuana. This review examines major considerations
when developing these threshold THC concentrations and specifics of legal THC limits for drivers adopted by
different jurisdictions in the United States and other countries.
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Drugged driving is a safety concern of increasing importance
in the United States and in Europe (Asbridge 2014; Brady
and Li 2014; Li et al. 2013; Whitehill et al. 2014; Wolff
and Johnston 2014). According to the 2012 National
Survey on Drug Use and Health, 10.3 million individuals
aged 12 years or older operated a motor vehicle under the
influence of illicit drugs in 2011 (SAMHSA 2013). Driving
under the influence of drugs has also been identified as a
priority area for drug control research and interventions
by the Office of National Drug Control Policy and the De-
partment of Transportation (ONDCP 2013). Marijuana,
the most commonly detected non-alcohol substance in
American and European drivers, has been shown to
impair driving performance and cognitive functions and
increase crash risk (Asbridge 2014; Downey et al. 2013;
Hartman and Huestis 2013; Li et al. 2013; Ramaekers
et al. 2004, 2006; Schwope et al. 2012). While driving
under the influence of marijuana is prohibited in all US
states (Walsh 2009), there has been a significant rise in
marijuana decriminalization and medical marijuana
legalization over the past decade (NORML) 2014c; Svrakic
et al. 2012; Wolff and Johnston 2014). Recreational* Correspondence: gl2240@cumc.columbia.edu
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in any medium, provided the original work is pmarijuana use is also currently legal in Colorado and
Washington (Asbridge 2014; Barry et al. 2014; Kilmer
2014). The recent increase in marijuana accessibility
(Sewell et al. 2009; Whitehill et al. 2014) underscores the
need for effective legislation to combat potential health
and safety risks posed by driving under the influence
of marijuana (Grotenhermen et al. 2007; Whitehill et al.
2014).
In collaboration with the National Highway Traffic
Safety Administration (NHTSA) and the International
Association of Chiefs of Police (IACP), law enforcement
agencies have developed drug evaluation and classifica-
tion (DEC) programs in the United States since 1989
(DuPont et al. 2012; Romano and Voas 2011; Talpins
and Hayes 2004). DEC programs are the principal legal
strategy to enforce drugged driving legislation, and train
police officers to recognize signs of drug-induced
impairment in drivers [e.g., bloodshot eyes, increased
nervousness, etc. (Wolff and Johnston 2014)], qualifying
them as drug recognition experts (DREs) (ONDCP 2010;
Asbridge 2014; Talpins and Hayes 2004; Walsh 2009).
Similar programs also exist in Europe (EMCDDA 2009;
Verstraete et al. 2011), but as of 2009, training was
required for traffic police in only 4 countries (Belgium,
Portugal, Sweden, and United Kingdom) (EMCDDA
2009). If a case involving a drugged driver goes to trial
and a DRE was present at the scene, the DRE may testifyn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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the degree of the driver’s impairment DuPont et al.
2012; Talpins and Hayes 2004). In the United States,
over 6,000 law enforcement officers have been certified
as DREs (ONDCP 2010). Although DREs have increased
the number of drugged driving arrests, DRE evaluations
are generally only performed when a driver’s blood
alcohol concentration (BAC) results are inconsistent
with the driver’s performance on Standardized Field
Sobriety Tests (Talpins and Hayes 2004). The limited
use of DRE evaluations means that drugged drivers with
high BACs may bypass DRE evaluations, leading to
underreporting of drugged driving (EMCDDA 2009).
Furthermore, in the absence of specified legal limits for
drugs in most states and countries, the value of DRE
evaluation and drug testing results as evidence in court
is limited. This review examines major considerations
when establishing legal limits of Δ9-tetrahydrocanna-
binol (THC) for drivers and specifics of per se laws
regarding driving under the influence of marijuana




There are currently three principal approaches to the
assessment and control of drugged driving in the United
States. The first approach is “effect-based,” by which
prosecutors must prove that the drug impaired the
driver’s ability to operate a motor vehicle (Grotenhermen
et al. 2007). Although this approach is implemented in
the majority of states in the United States, it is difficult
and complex to enforce, particularly due to the lack of
standardization in methods of assessing and determining
drug-induced impairment (Kay and Logan 2011; Romano
and Pollini 2013). A uniformly accepted definition of
impairment does not exist for different drugs, and these
definitions vary across states (DuPont et al. 2012).
Laboratory analysis of blood or urine samples is also
expensive and time-consuming, and in general, these
tests are only performed if a driver has a BAC within the
legal limit (<0.08%) (DuPont et al. 2012). As a result, in
comparison to drunk driving, drugged driving is rarely
prosecuted in the United States (DuPont et al. 2012;
Walsh 2009).
Due to the limitations of the effect-based approach,
some states have adopted “per se” laws, which make it a
criminal offense for an individual to have a specified
amount of drug or metabolite in his or her body while
operating a motor vehicle (Asbridge 2014; DuPont et al.
2012; Grotenhermen et al. 2007; Lacey et al. 2010). This
threshold concentration is a legal limit, and exceeding
this amount serves as proof of legal impairment
(Asbridge 2014; Ramaekers et al. 2006).The third approach is the “zero tolerance” policy, a
special form of the per se law in which the legal limit is
set at zero or the minimum reliably detectable level
(Asbridge 2014; Grotenhermen et al. 2007; Lacey et al.
2010; Reisfield et al. 2012; Salomonsen-Sautel et al.
2014). However, zero tolerance laws pose several short-
comings. Such laws incriminate drivers whose bodily
fluids contain any amount of drug or metabolite, and
who therefore may not actually be impaired while driv-
ing (Grotenhermen et al. 2007; Ramaekers et al. 2006).
This issue is exacerbated for marijuana use. THC has a
half-life of approximately 7 days, and the total elimin-
ation of a single dose from one’s urine can take up to
30 days (Ashton 2001; Bedard et al. 2007). Due to its
relatively long half-life, THC can be detected in the
blood and urine of an individual for hours to days and
for days to months following marijuana use, respectively,
depending on the frequency of use and other factors
(NORML 2014b; Asbridge 2014; Grotenhermen et al.
2007; NORML 2014b). For instance, chronic marijuana
users have plasma THC concentrations ranging from
1.0 μg/L to 11.0 μg/L, which are maintained by the con-
tinual passage of THC from the tissues into the blood-
stream (Wolff and Johnston 2014). Therefore, habitual
users who test positive for THC may not necessarily be
impaired at the time of testing (Bedard et al. 2007).
Another major limitation of zero tolerance laws is the
risk to convict those with heavy passive exposure to
marijuana smoke (Grotenhermen et al. 2007; Wolff and
Johnston 2014). Following passive exposure, the THC of
an individual may be detectable in his blood in concen-
trations <1.0 μg/L within one hour, without inducing
concurrent impairment (Grotenhermen et al. 2007;
Sharma et al. 2012; Wolff and Johnston 2014).
European countries also use different legal approaches
in tackling drugged driving (EMCDDA 2009; Verstraete
et al. 2011). The impairment approach, which is compar-
able to the effect-based law in the United States, is
enforced in 11 European countries (Gjerde et al. 2011a;
Verstraete et al. 2011; Wolff and Johnston 2014). Like
some US states, five European countries employ per se
laws, which prosecute a driver if his body fluid surpasses
a defined cut-off concentration (Gjerde et al. 2011a;
Vindenes et al. 2012; Wolff and Johnston 2014). As in
the US, zero tolerance laws in European countries also
fall under the per se category (Verstraete et al. 2011;
Wolff and Johnston 2014). Nine European countries
have adopted the “two-tier system,” a combination of
the impairment-based law and the per se law. The two-
tier system penalizes drivers with any amount of an illicit
drug in his body with a non-criminal or lower-level
criminal fine, and more severely penalizes drivers who
are impaired by any substance (EMCDDA 2009; Verstraete
et al. 2011).
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Method of marijuana consumption
The rate of marijuana absorption into the bloodstream
and body tissues is determined by the route of drug
administration (Huestis 2007). Inhalation and ingestion
of marijuana produce psychoactive effects of different
duration and intensities (Grotenhermen et al. 2007; Hall
and Degenhardt 2009; Schwope et al. 2012; Wolff and
Johnston 2014). When smoking marijuana is the princi-
pal method of consumption, there is a fast release of
THC via inhalation into the general circulation (Huestis
2007). Subsequent absorption of inhaled THC is also
rapid (Wolff and Johnston 2014), and THC can be de-
tected within seconds after the initial puff of a cigarette
(Schwope et al. 2012). Blood concentrations typically
reach a maximum within 3 to 15 minutes of intake
(Verstraete 2004; Wolff and Johnston 2014). Furthermore,
the quantity of marijuana in an average rolled cigarette is
about 200 mg, which is equivalent to approximately 5 mg
to 30 mg active THC (Wolff and Johnston 2014). On the
other hand, absorption of orally ingested forms of THC
occurs slowly and unpredictably due to its high octanol/
water partition coefficient (Huestis 2007) and its passage
through the gut (Wolff and Johnston 2014). Maximal
blood concentrations are lower for ingested marijuana
(Huestis 2007), and are reached between 1 and 7 hours
after consumption (Huestis 2007; Wolff and Johnston
2014). Edibles (ingested forms of marijuana) also contain
varied amounts of THC (e.g., brownies, pumpkin cake,
chocolate cookie), ranging from 20 mg to 64 mg (Huestis
2007; Wolff and Johnston 2014).
Frequency of marijuana use
Occasional and recreational users have lower plasma
THC concentrations than regular and frequent users
(Downey et al. 2013; Wolff and Johnston 2014). How-
ever, the effect of THC consumption on impairment of
driving performance may be higher for occasional
marijuana users than for frequent users (Bosker et al.
2012; Downey et al. 2013). A meta-analysis of more than
120 studies demonstrated that regular users were less
impaired than occasional users at the same THC
concentration (Wolff and Johnston 2014), which may
be attributed to physiological tolerance or learned
compensatory driving behavior (DuPont et al. 2012;
Grotenhermen et al. 2007; Wolff and Johnston 2014).
Habitual users are more susceptible to experiencing
chronic, long-term effects of marijuana, including
withdrawal symptoms and developing addiction to the
drug (Ashton 2001; Hall and Degenhardt 2009; Karila
et al. 2014; Lee et al. 2014). On the other hand, infre-
quent users are more prone to experiencing stronger
acute effects, like impairment (Hall and Degenhardt2009; Karila et al. 2014; Moskowitz 1985; Wolff and
Johnston 2014).
Concurrent use of marijuana and alcohol
According to toxicological testing data, approximately
25% of drivers injured in motor vehicle crashes test posi-
tive for 2 or more drugs, with marijuana and alcohol be-
ing the most common combination (Brady and Li 2013;
Kay and Logan 2011; Li et al. 2013). Wilson et al. (2014)
found that 54.9% of marijuana-positive drivers in the
United States had elevated BACs. Various studies have
demonstrated that the combined use of marijuana and
alcohol is associated with significantly greater cognitive
impairment and crash risk than the use of one alone
(Asbridge 2014; Downey et al. 2013; Ramaekers et al.
2004; Sewell et al. 2009).
Polydrug use
Another major factor to be considered when developing
per se laws is polydrug use, or the use of 2 or more non-
alcohol drugs (Brady and Li 2013; Hartman and Huestis
2013; Li et al. 2013; Romano and Voas 2011). In Europe,
20-30% of marijuana use among drivers was combined
with other psychoactive substances in 2012, with marijuana
being the most frequently detected drug used simultan-
eously with cocaine and benzodiazepines (Wolff and
Johnston 2014). Li et al. (2013) found that polydrug use
was associated with a 3.41-fold increased risk of involve-
ment in a fatal crash. Legislation for multiple drug use is
complicated, for limited drug-drug combinations have
been fully characterized in the context of drugged driv-
ing, and possible interactions range widely (Wolff and
Johnston 2014). This makes it difficult for police officers
to recognize impairment induced by several drugs and to
conduct simultaneous roadside screenings for multiple
substances (Wolff and Johnston 2014).
Testing method and specimen collection
In order to measure the level of THC present in a driver,
states conduct chemical screening tests via collection of
the driver’s blood, urine, and/or oral fluid (OF) (NORML
2014a; Walsh 2009). Blood sampling is the most effective
method, but it is also the most invasive (Wolff and
Johnston 2014). There is a lack of standardization
regarding blood sample collection (i.e., duration of time
after a driver is pulled over is his blood to be collected)
and transportation conditions to a collection facility
(e.g., hospital) as well. In addition, blood screening can
also detect metabolites of THC [e.g., carboxy-THC
(THC-COOH)] (NORML 2014b). However, detection of
THC-COOH only (no THC) does not indicate impair-
ment (NORML 2014b; Sewell et al. 2009). Furthermore,
active 11-hydroxy-THC, a metabolite that continues to
produce effects in the body after being metabolized, is
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smoking marijuana (Himes et al. 2013). Therefore, there
is little cross-reaction from active 11-hydroxy-THC and
inactive metabolites with THC-COOH antibodies,
which would typically cause extension of a screening
test’s detection window (Wolff and Johnston 2014).
The majority of states in the United States also
conduct urine screening tests, or urinalyses (NORML
2014a; Walsh 2009). Urine screening tests are generally
performed via immunoassays that can detect combina-
tions of THC and its metabolites, but not necessarily
THC alone (Sewell et al. 2009; Wolff and Johnston
2014). Therefore, urinalysis is only reflective of previous
marijuana exposure, rather than degree of impairment
by the drug (Huestis 2007; Sewell et al. 2009; Wolff and
Johnston 2014).
Recently, there has been strong interest in collecting
bodily fluids other than blood and urine in order to fa-
cilitate roadside drug testing (Himes et al. 2013; Huestis
2007). The use of OF to determine a driver’s THC level
has gained popularity in the United States, for it is the
easiest and least invasive method (Himes et al. 2013;
Wolff and Johnston 2014). Australia currently collects
OF samples for its random roadside marijuana testing
programs (Asbridge 2014; Chu et al. 2012; Davey and
Freeman 2009; Wolff and Johnston 2014). Samyn et al.
(1999) demonstrated that OF reflects whether an indi-
vidual has a drug present in his blood better than urine
(Gjerde et al. 2011b). Although the THC concentration
in OF correlates strongly with that in blood on the
population level, it remains problematic to estimate
blood THC concentrations based on OF samples for in-
dividual drivers (Gjerde et al. 2011b; Ramaekers et al.
2006). In addition, OF sample volumes are significantly
lower than those for urine, potentially resulting in insuf-
ficient specimen for confirmation testing (Huestis et al.
2011). Numerous studies have investigated whether OF
THC concentration is an accurate measure of blood
THC concentration as an indicator of driving impair-
ment (Gjerde et al. 2011b; Wolff and Johnston 2014). A
study conducted by Ramaekers et al. (2006) found that
there was a linear relationship between magnitude of
performance impairment and THC level in OF, and that
OF containing THC may be indicative of recent exposure
to or consumption of marijuana.
Pharmacokinetics
THC is extremely lipid soluble (Ashton 2001; Huestis
2007; Nahas 2001; Wolff and Johnston 2014), and is
widely distributed in the body to tissues at rates
dependent on blood flow (Ashton 2001). THC in blood
rapidly decreases over time (Huestis 2007), typically
declining to 1.0-4.0 μg/L within 3–4 hours (Wolff and
Johnston 2014). Therefore, delayed blood collectionoften results in an inaccurate THC measurement, which
may not be reflective of a driver’s level of impairment
while driving. Depending on the frequency of marijuana
use, THC in blood can be detectable for hours to
days following the most recent use (NORML 2014b;
Verstraete 2004). In addition, THC and THC-COOH are
predominantly detected in blood plasma, where 95-99%
of the metabolites are bound to lipoproteins (Huestis
2007). THC concentrations in whole blood are approxi-
mately one-half the concentrations in plasma (Barceloux
2012; Huestis 2007).
Marijuana as detected by urinalysis has a long-ranging
detection window in regular and non-regular users,
primarily due to metabolic cross-reaction between active
11-hydroxy-THC and inactive metabolites (Wolff and
Johnston 2014). Detection times in urine depend on
pharmacological factors, including method of THC
consumption and the metabolism rate of an individual
(Huestis 2007), and metabolites are typically not detect-
able in urine for up to 4 hours (Wolff and Johnston
2014). Metabolites can be detected in urine for several
days or months, contingent upon the frequency of use
(NORML 2014b; Ramaekers et al. 2006; Verstraete
2004). Due to the long detection window of THC in
urine (Wolff and Johnston 2014), a positive immunoassay
test may only be indicative of previous use (Huestis 2007;
Ramaekers et al. 2004; Wolff and Johnston 2014). The
long excretion half-life of THC-COOH, particularly in
chronic marijuana users, makes it difficult to determine
the timing of past drug use (Huestis 2007).
There is little to no THC-COOH metabolite present
in OF (Huestis 2007), meaning the detection window for
OF is not overextended due to any metabolite cross-
reaction (Himes et al. 2013; Wolff and Johnston 2014).
Since detection times of cannabinoids in OF are shorter
(i.e., hours to days after use) (Verstraete 2004; Wolff and
Johnston 2014), OF is more reflective of recent cannabis
use than urine (Huestis 2007). Furthermore, during the
smoking of marijuana, the oral mucosa is exposed to
high THC concentrations, serving as the main source for
release of THC into OF (Huestis 2007; Huestis and Cone
2004). Peak OF THC concentrations of 5800 μg/L have
been reported immediately after smoking marijuana,
followed by 30 minutes of rapid elimination and a subse-
quent slower decrease (Huestis and Cone 2004; Wolff
and Johnston 2014).
Legal THC limits for driving adopted by different
jurisdictions
In the United States, there are currently seven states that
enforce legal marijuana metabolite limits for drivers
(Colorado, Iowa, Montana, Nevada, Ohio, Pennsylvania,
and Washington) (Table 1). With the exception of Iowa,
all of these states list legal THC thresholds in whole
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Nevada, Ohio, and Pennsylvania have set legal THC
and/or THC-COOH limits in urine. It is important to
note that the drugged driving legislation for Iowa
specifies a legal limit for THC-COOH, not for THC,
most likely because urine screening tests cannot detect
THC alone. Despite this limitation of urinalysis, Nevada,
Ohio, and Pennsylvania specified legal concentrations of
THC in urine. In addition, these states have legal limits
for both THC as well as its metabolites (THC-COOH).
Ohio also enforces a legal limit for THC-COOH “in
combination with alcohol or other drugs” to account
for the heightened impairment caused by the use of
marijuana with other drugs. Furthermore, all seven
states collect at least one specimen for marijuana testing,
but respective limits are not indicated for all collected
specimens (Table 1). For instance, in Colorado, a driver’s
blood, urine, and OF may be collected, but state
legislation only denotes a legal THC limit in blood. Drug
screenings based on an unspecified specimen provide
preliminary positive/negative tests, which reflect whether
an individual has any amount of drug in his body
regardless of potential impairment. A positive screening
test gives a police officer reasonable cause to ask the
driver to provide a blood sample to quantify his THC
level. If a driver refuses to participate in this initial
screening process, his test is considered positive.
Sixteen countries in Europe have set legal non-zero
THC concentrations at or above which drivers are prose-
cuted for driving under marijuana (Table 2). Of these
countries, eleven enforce legal limits in whole blood
(Denmark, Finland, France, Greece, Ireland, Italy, Norway,
Poland, Portugal, Switzerland, and United Kingdom), and
four enforce legal limits in blood serum (Belgium,
Germany, Luxembourg, and Slovenia). Netherlands hasTable 1 Legal Δ9-tetrahydrocannabinol (THC) thresholds for d
State Legal THC limit
Colorado 5.0 μg/L in blood
Iowa THC-COOH: 50.0 μg/L in urine
Montana 5.0 μg/L in blood
Nevada THC: 10.0 μg/L in urine, 2.0 μg/L in blood THC-COOH:
15.0 μg/L in urine, 5.0 μg/L in blood
Ohio THC: 10.0 μg/L in urine, 2.0 μg/L in blood THC-COOH:
35.0 μg/L in urine, 50.0 μg/L in blood THC-COOH in
combination with alcohol or other drugs: 15.0 μg/L
in urine, 5.0 μg/L in blood
Pennsylvania THC or THC-COOH: 1.0 μg/L in blood or urine
Washington 5.0 μg/L in blood
Abbreviations: OF oral fluid, THC Δ9-tetrahydrocannabinol, THC-COOH carboxy-Δ9-tet
Sources: (NORML). Drugged Driving. Washington, D.C. 2014a. http://norml.org/legal/
Per Se Laws: A Review of Their Use in States. Washington, D.C.: National Highway T
Minimum Levels of Controlled Substances or Their Metabolites in Blood to Establish
Accessed July 23 2014.; Wash Rev Code § 46.61.502); Walsh JM. A State-by-State An
D.C.: National Highway Traffic Safety Administration (NHTSA). 2009. Accessed July 1implemented legal limits in both blood and blood serum.
Unlike the United States, no European countries have
set legal THC limits in urine. Furthermore, several
European countries enforce legal thresholds for both
THC and its metabolite THC-COOH (Table 2).
Recommendations for future research
To further understand the safety risk posed by marijuana
use, more studies investigating the effects of marijuana
on impaired driving should be conducted. Further
research is also needed to provide the scientific basis for
developing legal THC limits for population groups other
than drivers, such as those working in safety-sensitive
positions.
In addition, it is necessary to standardize testing
protocols for each collected specimen (i.e., blood, urine,
and OF). This would resolve the current variation in
duration of time after a driver is pulled over or involved
in a motor vehicle crash that his body fluid is collected.
By limiting the decline of THC in the body over time,
standardization of testing conditions would enable police
officers to more accurately determine a driver’s degree
of impairment while driving.
The rise in technology has led to the proposal of novel
drug testing methods. Some studies have examined the
possible detection of THC in breath, a noninvasive and
easily observed drug screening method (Beck 2014;
Himes et al. 2013). Himes et al. (2013) found that
chronic and occasional smokers who smoked a single
marijuana cigarette experienced significant decreases in
THC breath concentration after controlled smoking.
The window for detecting cannabinoids in breath ranged
from 0.5 to 2 hours and coincided with impairment.
THC-COOH was also undetected in both groups of
marijuana smokers, indicating that legal marijuanarivers in states with per se laws
Collected specimen Year effective
Blood, urine, or OF 2013
Blood or urine 2010
Blood 2013
Blood, urine, or other bodily substance 2003
Blood, urine, or other bodily substance 2006
Blood or urine 2011
Blood 2013
rahydrocannabinol.
drugged-driving. Accessed July 15 2014.; Lacey J, Brainard K, Snitow S. Drug
raffic Safety Administration (NHTSA). 2010. Accessed July 15 2014.; Avila EN.
Presence of Controlled Substance. Pennsylvania Bulletin. 2011 April 30.
alysis of Laws Dealing With Driving Under the Influence of Drugs. Washington,
2 2014.
Table 2 Types of drugged driving legislation and legal Δ9-tetrahydrocannabinol (THC) thresholds for drivers in
European countries
Country Legislation Legal THC limit
Belgium Two-tier 1.0 μg/L in blood serum
Denmark Two-tier 1.0 μg/L in blood
Finland Two-tier THC: 1.0 μg/L in bloodTHC-COOH: 5.0 μg/L in blood
France Two-tier 1.0 μg/L in blood
Germany Two-tier 1.0 μg/L in blood serum
Greece Impairment 1.0 μg/L in blood
Ireland Impairment THC: 2.0 μg/L in bloodTHC-COOH: 5.0 μg/L in blood
Italy Per se THC or THC-COOH: 0.5 μg/L in blood
Luxembourg Impairment 2.0 μg/L in blood serum
Netherlands * 3.0 μg/L in blood**5.0 μg/L in blood serum
Norway Impairment 1.3 μg/L in blood***
Poland Per se THC: 2.0 μg/L in bloodTHC-COOH: 50.0 μg/L in blood
Portugal Per se THC: 3.0 μg/L in bloodTHC-COOH: 5.0 μg/L in blood
Slovenia Per se THC: 0.3 μg/L in blood serumTHC-COOH: 5.0 μg/L in blood serum
Switzerland Per se 1.5 μg/L in blood
United Kingdom**** Impairment THC: 2.0 μg/L in bloodTHC-COOH: 10.0 μg/L in blood
*Impairment as of 2011, but a proposal for a two-tier system has been implemented.
**Recommended by Netherlands Advisory Committee.
***Norway specified THC levels comparable to BAC (with regard to severity of impairment): 3.0 μg/L in blood is comparable to 0.05% BAC; 9.0 μg/L in blood is
comparable to 0.12% BAC.
****Initial drug screening is conducted via Drugalyser oral swab tests. A positive test could lead to a blood sample test to quantify THC level.
Abbreviations: THC Δ9-tetrahydrocannabinol, THC-COOH carboxy-Δ9-tetrahydrocannabinol.
Sources: Verstraete A, Knoche A, Jantos R, Skopp G, Gjerde H, Vindenes V et al. Driving under the Influence of Drugs, Alcohol and Medicines (DRUID): Per se limits -
Methods of defining cut-off values for zero tolerance. 2011. Accessed July 20 2014; Wolff K, Johnston A. Cannabis use: a perspective in relation to the proposed
UK drug-driving legislation. Drug Test Anal. 2014; 6(1–2):143–54.
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not THC-COOH, when a breath test is conducted. The
short detection window for THC indicates that breath
may be a viable alternative to OF for detecting marijuana
use, but only when a driver is tested <2 hours following
smoking. There is also a lack of knowledge regarding the
effect of passive marijuana exposure on breath THC
concentrations (Himes et al. 2013). Further research is
needed to investigate the effectiveness of breath testing
to assess a driver’s degree of impairment. There is also
some interest in the use of sweat as an alternative bio-
logical matrix for detecting the recent use of marijuana
(De Giovanni and Fucci 2013; de la Torre and Pichini
2004; Huestis et al. 2008). Sweat testing is non-invasive
(Huestis et al. 2008) and is typically collected via dermal
patches or wipes (De Giovanni and Fucci 2013; de la
Torre and Pichini 2004; Huestis et al. 2008), which en-
able illicit drug use to be monitored for longer detection
windows than those for urine testing (de la Torre and
Pichini 2004). However, research examining the presence
of THC excretion in sweat is limited (de la Torre and
Pichini 2004; Huestis et al. 2008). Some studies have
investigated the effectiveness of dermal wipes to collect
the sweat of drugged drivers. While THC was detected,
11-hydroxy-THC and THC-COOH were not (Huestiset al. 2008). Sweat testing is further limited by difficulties
in sample recovery (de la Torre and Pichini 2004). In
addition, the amount of THC in sweat is significantly
low, and therefore requires sensitive analytical methods
(De Giovanni and Fucci 2013; de la Torre and Pichini
2004).
Conclusions
There is compelling evidence that marijuana use impairs
cognitive functions and driving skills and increases crash
risk. Due to the limitations of impairment-based and
zero tolerance laws, governments are increasingly adopt-
ing per se limits at which a driver is legally defined as
being impaired to safely operate a motor vehicle. Some
countries in Europe have also adopted a two-tier system,
which incorporates both impairment-based and per se
approaches. Several factors should be considered for the
establishment of per se laws, including a driver’s mode
of marijuana consumption, frequency of use, and the
concurrent use of marijuana with other drugs. In order
to assess a driver’s THC level, police officers administer
drug screenings via collection of blood, urine, and/or OF
samples. It is imperative to consider the pharmacokinetics
of THC, including its rapid decline in blood over time, to
facilitate standardization of drug testing. Future work
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ship between THC levels and crash risk, establishing legal
THC limits for other population groups, especially those
with safety-sensitive occupations, and developing innova-
tive marijuana testing methods, such as those using OF
and breath samples.
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